Search results for: COVID-19

BSWRI opens variant-focused monoclonal antibody trial with Eli Lilly

BSWRI’s most recent COVID-19 research endeavor was featured in an exclusive story published by the Dallas Morning News as well as a number of other local and national outlets. The trial examines a new monoclonal antibody, produced by Eli Lilly and AbCellera Biologics, which has been shown to neutralize all known variants of concern in early lab tests.

Read more

BSWRI study delivers new data around impact of masking on exercise performance

Masks are recognized as important tools in the fight against the COVID-19 pandemic. To save medical-grade masks for hospital personnel, people have adopted reusable cloth masks for everyday use. Researchers have studied the efficacy of mask use, but what about the effects of wearing a cloth face mask on sports performance? A new study by Baylor Scott & White Research Institute (BSWRI) has now shed light on the matter. The research team at Baylor Scott & White Sports Therapy & Research at The Star in Frisco, conducted a study on the effects of cloth mask use during exercise. Their work, which shows that cloth masks reduce exercise performance at a range of intensities, was published in the British Journal of Sports Medicine last month.

Read more

Pathology preparedness and a scalable pandemic response

The 2020 COVID-19 pandemic associated with the novel SARS-CoV-2 virus has required an unprecedented mobilization of resources worldwide. One of the cornerstones to pandemic response is rapid initiation of widespread testing. To meet this need, physicians and researchers at Baylor Scott & White Research Institute were quick to establish reliable testing for SARS-CoV-2 virus, and their experience can serve as a guide for the response to future novel infectious diseases.

Read more

Eli Lilly’s BLAZE clinical trials offer new therapeutic insights for treating COVID-19

Since the beginning of the COVID-19 pandemic, researchers have been racing to identify therapeutics that prevent the progression of SARS-CoV-2 infection to serious disease. Although vaccine rollout is ongoing, SARS-CoV-2 infection rates are increasing nationwide and there is an urgent need for life-saving interventions.  Results of the BLAZE clinical trials involving LY-CoV555, an antibody against the SARS-CoV-2 spike protein, provide context on these therapeutic possibilities. This research is being conducted through multiple Baylor Scott & White Research Institute (BSWRI) sites across Texas.

Read more